Abstract: The present invention relates to guidance during a medical intervention. In order to provide an improved navigation support with a facilitated setup, a system (10) for navigation support is provided. An image data input (12) receives a plurality of acquired 2D X-ray images of a subject's body from different angles. A set of markers, which are visible in X-ray images and which are detectable by a navigation system, is assigned to the subject. A marker detecting arrangement (16) is provided that detects a current spatial location of the markers assigned to the subject. A data processor (14) reconstructs a 3D volume of the subject based on the plurality of 2D X-ray images. At least a part of the markers is arranged outside the volume covered by the reconstructed 3D volume of the subject, while the markers are visible in the 2D X-ray images.

Abstract: Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of any intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.

Abstract: Disclosed is apparatus for administration of a drug in active form, which includes means defining a prodrug reaction zone including an immobilized enzyme for modifying chemically a prodrug to a physiologically compatible, physiologically active drug form, means in communication with the reaction zone for establishing parenteral access to the body of a patient, and means for transporting a prodrug through the reaction zone at a rate sufficient to convert the prodrug to the active drug form and then into the body of a patient.

Abstract: Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of an intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.

Abstract: A method for the detection of malignant leukocytic cells which comprises:contacting a fluid containing malignant leukocytic cells with a merocyanine dye of the formula: ##STR1## wherein n=1-5; X=0 or S; R.sub.1 and R.sub.2 are the same or different C.sub.2 -C.sub.5 alkyl groups:wherein said dye is incorporated into said cells; separating the cells from the incubation mixture; and detecting said dyed cells. Fluorescence or radioactivity detection methods are preferred detecting means.

Abstract: A plasminogen proactivator and a corresponding activator has been isolated from mammalian and avian, especially human, plasma which is characterized within a given species as a single, electrophoretically and immunologically homogeneous protein. The activator acts as a catalyst to initiate fibrinolytic activity in plasma and is therefore useful in controlling clotting which occurs, e.g. in venous thrombosis or arterial occulsion, and in diagnosing conditions which predispose to thromboembolic phenomena. The proactivator has a long useful in vivo half life and can be used to provide a reservoir for maintaining the fibrolytic potential of blood.